Literature DB >> 15890457

Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue.

R H Andres1, A W Huber, U Schlattner, A Pérez-Bouza, S H Krebs, R W Seiler, T Wallimann, H R Widmer.   

Abstract

Parkinson's disease is a disabling neurodegenerative disorder of unknown etiology characterized by a predominant and progressive loss of dopaminergic neurons in the substantia nigra. Recent findings suggest that impaired energy metabolism plays an important role in the pathogenesis of this disorder. The endogenously occurring guanidino compound creatine is a substrate for mitochondrial and cytosolic creatine kinases. Creatine supplementation improves the function of the creatine kinase/phosphocreatine system by increasing cellular creatine and phosphocreatine levels and the rate of ATP resynthesis. In addition, mitochondrial creatine kinase together with high cytoplasmic creatine levels inhibit mitochondrial permeability transition, a major step in early apoptosis. In the present study, we analyzed the effects of externally added creatine on the survival and morphology of dopaminergic neurons and also addressed its neuroprotective properties in primary cultures of E14 rat ventral mesencephalon. Chronic administration of creatine [5 mM] for 7 days significantly increased survival (by 1.32-fold) and soma size (by 1.12-fold) of dopaminergic neurons, while having no effect on other investigated morphological parameters. Most importantly, concurrent creatine exerted significant neuroprotection for dopaminergic neurons against neurotoxic insults induced by serum and glucose deprivation (P < 0.01), 1-methyl-4-phenyl pyridinium ion (MPP+) [15 microM] and 6-hydroxydopamine (6-OHDA) [90 microM] exposure (P < 0.01). In addition, creatine treatment significantly protected dopaminergic cells facing MPP+-induced deterioration of neuronal morphology including overall process length/neuron (by 60%), number of branching points/neuron (by 80%) and area of influence per individual neuron (by 60%). Less pronounced effects on overall process length/neuron and number of branching points/neuron were also found after 6-OHDA exposure (P < 0.05) and serum/glucose deprivation (P < 0.05). In conclusion, our findings identify creatine as a rather potent natural survival- and neuroprotective factor for developing nigral dopaminergic neurons, which is of relevance for therapeutic approaches in Parkinson's disease and for the improvement of cell replacement strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890457     DOI: 10.1016/j.neuroscience.2005.03.004

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  27 in total

1.  Inhibition of cytosolic and mitochondrial creatine kinase by siRNA in HaCaT- and HeLaS3-cells affects cell viability and mitochondrial morphology.

Authors:  Holger Lenz; Melanie Schmidt; Vivienne Welge; Thomas Kueper; Uwe Schlattner; Theo Wallimann; Hans-Peter Elsässer; Klaus-Peter Wittern; Horst Wenck; Franz Staeb; Thomas Blatt
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

Review 2.  The mitochondrial permeability transition in neurologic disease.

Authors:  M D Norenberg; K V Rama Rao
Journal:  Neurochem Int       Date:  2007-03-04       Impact factor: 3.921

3.  Development and validation of a screening assay for the evaluation of putative neuroprotective agents in the treatment of Parkinson's disease.

Authors:  C J Yong-Kee; D Salomonczyk; J E Nash
Journal:  Neurotox Res       Date:  2010-04-02       Impact factor: 3.911

Review 4.  The creatine kinase system and pleiotropic effects of creatine.

Authors:  Theo Wallimann; Malgorzata Tokarska-Schlattner; Uwe Schlattner
Journal:  Amino Acids       Date:  2011-03-30       Impact factor: 3.520

5.  Treatment by oral creatine, L-arginine and L-glycine in six severely affected patients with creatine transporter defect.

Authors:  Vassili Valayannopoulos; Nathalie Boddaert; Allel Chabli; Valerie Barbier; Isabelle Desguerre; Anne Philippe; Alexandra Afenjar; Michel Mazzuca; David Cheillan; Arnold Munnich; Yves de Keyzer; Cornelis Jakobs; Gajja S Salomons; Pascale de Lonlay
Journal:  J Inherit Metab Dis       Date:  2011-06-10       Impact factor: 4.982

6.  A new multistep induction protocol for the transdifferentiation of bone marrow stromal stem cells into GABAergic neuron-like cells.

Authors:  Shahram Darabi; Taki Tiraihi; AliReza Delshad; Majid Sadeghizadeh
Journal:  Iran Biomed J       Date:  2013

Review 7.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 8.  Beyond muscles: The untapped potential of creatine.

Authors:  Lisa A Riesberg; Stephanie A Weed; Thomas L McDonald; Joan M Eckerson; Kristen M Drescher
Journal:  Int Immunopharmacol       Date:  2016-01-08       Impact factor: 4.932

Review 9.  Mitochondria: a therapeutic target in neurodegeneration.

Authors:  Paula I Moreira; Xiongwei Zhu; Xinglong Wang; Hyoung-Gon Lee; Akihiko Nunomura; Robert B Petersen; George Perry; Mark A Smith
Journal:  Biochim Biophys Acta       Date:  2009-10-21

10.  Chronic creatine supplementation alters depression-like behavior in rodents in a sex-dependent manner.

Authors:  Patricia J Allen; Kristen E D'Anci; Robin B Kanarek; Perry F Renshaw
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.